Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)

This grant program, entitled Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional), aims to identify and optimize neurophysiological measures as potential assays for advancing treatment developments. The grant is open to projects focused on exploring these measures in both healthy humans and other species that may be relevant to therapeutic development.

A key phase supported by this grant is the initial proof of concept studies. These studies are intended to help identify measures that could possibly be used to develop preclinical assays. These assays would be used to evaluate the potential efficacy of new drug and device therapies and their specific targets.

Moreover, through the data gathered, discrepancies between the performances of preclinical animal species and humans can be identified. This information will establish a solid foundation for limiting speculative extrapolations from animal-based preclinical findings to humans, thereby increasing the accuracy and efficacy of research.

Ultimately, the practical aim of this grant is to create a more efficient therapeutic development process. By identifying measure consistencies and disparities between preclinical screenings and clinical evaluations of new treatment candidates, the grant intends to speed up the development of effective treatments for mental disorders.